ABT241011P124000
- 7.04
- 0.000.00%
Abbott Laboratories Newsroom
Abbott Labs Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $130
Abbott Laboratories Analyst Ratings
Oppenheimer Initiates Coverage On Abbott Laboratories With Outperform Rating, Announces Price Target of $130
Oppenheimer Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $130
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $133 From $126
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Piper Sandler Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $131
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $130
Buy Rating on Abbott Laboratories: Strong Performance and Positive Outlook Amid New Product Launches
Abbott Labs Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $124
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Abbott Laboratories Analyst Ratings
Jefferies Maintains Abbott Laboratories(ABT.US) With Hold Rating, Maintains Target Price $120
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $133
Abbott Laboratories Analyst Ratings
Piper Sandler Initiates Abbott Laboratories(ABT.US) With Buy Rating, Announces Target Price $131
Buy Rating on Abbott Laboratories: Undervalued With Strong Growth Prospects Despite NEC Litigation